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Abstract
Purpose—We conducted gene-based analysis in 26 genes in the FGFR signaling pathway to 
identify genes carrying genetic variation affecting risk of breast cancer and the specific estrogen 
receptor (ER) subtypes.
Methods—Tagging single nucleotide polymorphisms (SNPs) for each gene were selected and 
genotyped on a customized Illumina Exome Array. Imputation was carried out using 1000 
Genomes haplotypes. The analysis included 3,237 SNPs in 3,663 breast cancer cases (including 
1,983 ER positive, and 1,098 ER-negative and 4,687 controls from the African American Breast 
Cancer Epidemiology and Risk consortium, a collaborative project of four large studies of breast 
cancer in African American women (Carolina Breast Cancer Study, Black Women's Health Study, 
Women's Circle of Health Study, and Multiethnic Cohort). We used a multi-locus adaptive joint 
(AdaJoint) test to determine the association of each gene in the FGFR signaling pathway with 
overall breast cancer and ER subtypes.
Results—The FGF1 gene was significantly associated with risk of ER negative breast cancer (P 
= 0.001). The FGFR2 gene was associated with risk of overall breast cancer (P = 0.002) and ER 
positive breast cancer (P = 0.002).
Conclusions—The FGF1 gene affects risk of ER negative breast cancer in African American 
women. We confirmed the association of the FGFR2 gene with risk of overall and ER positive 
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breast cancer. These results highlight the importance of the FGFR signaling pathway in the 
pathogenesis of breast cancer, and suggest that different genes in the same pathway may be 
associated with different ER breast cancer subtypes.
INTRODUCTION
Signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) regulates 
multiple cellular processes such as tissue repair, differentiation, survival, proliferation, and 
migration, among others (see reviews [1,2]). Deregulation of the FGF/FGFR signaling 
pathway through somatic alterations has been widely implicated in breast cancer [1-3]. Less 
is known about germline variation in the FGF/FGFR signaling pathway and risk of breast 
cancer. Only genetic variants in the FGFR2 gene have been consistently associated with risk 
of breast cancer, and they appear to be more strongly associated with estrogen-receptor (ER) 
positive tumors [4-8]. To date, no systematic evaluation of germline variation in the FGF/
FGFR signaling pathway in relation to breast cancer has been carried out. The Breast Cancer 
Association Consortium (BCAC) which includes predominantly European-ancestry subjects, 
evaluated genetic variation in four FGF gene receptors (FGFR1, FGFR3, FGFR4, and 
FGFRL1) and found little evidence of association with risk of breast cancer [9]. The Breast 
Cancer Health Disparities Study, which includes Hispanic and non-Hispanic white women, 
conducted gene-based analysis of seven growth factor genes including three genes in the 
FGF/FGFR signaling pathway (FGFR2, FGF1, and FGF2). FGFR2 was significantly 
associated with breast cancer risk only among those with ER+ tumors, and FGF1 showed 
borderline association with ER−/PR− breast cancer [10]. It is unclear whether other genes in 
the pathway may also carry breast cancer risk variants, and whether they may differentially 
affect risk of specific breast cancer subtypes. In addition, no systematic study of the FGF/
FGFR pathway in African American women has been conducted to date.
Because multiple independent single nucleotide polymorphisms (SNPs) with small to 
modest effect may be present in the same gene (e.g. at least three independent signals have 
been identified in the FGFR2 gene [11]), the standard single SNP analysis may fail to fully 
capture the joint effect of multiple SNPs in a given gene [12,13]. Gene-based tests provide a 
powerful alternative to the single SNP approach to combine the evidence of association from 
several genetic variants within a gene in relation to disease [14,15]. Gene-based tests have 
been successfully used to identify new loci in relation to height and body mass index [12], 
Crohn’s disease [16], and glucose and lipid levels [17] among others.
We postulate that common SNPs may act jointly in genes in the FGF/FGFR signaling 
pathway to affect risk of breast cancer. We evaluated this hypothesis through a 
comprehensive assessment of common genetic variation in FGFs, FGFRs, and downstream 
genes in the FGF/FGFR pathway in relation to breast cancer risk. We conducted this work in 
the African American Breast Cancer Epidemiology and Risk (AMBER) consortium, a 
collaborative project from four of the largest studies of breast cancer in African American 
women (Carolina Breast Cancer Study (CBCS), Black Women's Health Study (BWHS), 
Women's Circle of Health Study (WCHS), and Multiethnic Cohort (MEC)).
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MATERIALS AND METHODS
Study subjects
The CBCS [18], WCHS [19,20], BWHS [21], and MEC [22] – have been described 
previously. Each study was granted Institutional Review Board approval and all study 
subjects provided informed consent. Briefly, the CBCS is a population-based case-control 
study of women aged 20 to 74 years that began in North Carolina in 1993. Cases were 
identified through the North Carolina Central Cancer Registry’s rapid case ascertainment 
system, and controls were enrolled through 2001 using Division of Motor Vehicles lists (age 
< 65 years) and Health Care Financing Administration lists (age ≥ 65). Questionnaire data 
and samples for DNA analysis were obtained by interviewers in home visits. The WCHS is a 
case-control study that began in 2002 with ascertainment of cases aged 20 to 75 years from 
New York City hospitals, later expanding to several counties in New Jersey, with case 
identification using the New Jersey State Cancer Registry’s rapid case ascertainment system. 
Controls have been recruited through random digit dialing as well as community-based 
efforts. In-person interviewers collect risk factor data and obtain samples for DNA analysis.
The BWHS is a prospective cohort study that began in 1995 when 59,000 African American 
women 21-69 years of age from across the United States completed a postal health 
questionnaire. Breast cancer cases are identified by self-report in biennial follow-up 
questionnaires, and cases are confirmed by medical records or from state cancer registry data 
and the National Death Index. Approximately 27,000 BWHS participants have given saliva 
samples for DNA analysis. The MEC is a prospective cohort study in Hawaii and Southern 
California that began in 1993 with the enrollment of men and women aged 45-75 years. Data 
is collected through questionnaires mailed at 5-year intervals, and breast cancer cases are 
confirmed by linkage with the California and Hawaii state cancer registries and the National 
Death Index. Controls for BWHS and MEC were selected from among all non-cases in those 
studies.
Eligible cases for analysis were women with a first diagnosis of incident invasive breast 
cancer or ductal carcinoma in situ, with available DNA samples for genotyping. 
Determination of ER status for cases was based on pathology data from hospital records or 
cancer registry records.
Replication testing of the most significant SNPs was conducted in a subset of samples of the 
African American Breast Cancer (AABC) consortium, which included participants from 9 
epidemiological studies [23,24], after excluding MEC, WCHS, and CBCS subjects who 
were already included in AMBER. Genotype data from 1426 breast cancer cases (709 ER+, 
415 ER−, and 302 unknown ER status) and 927 controls were available from this reduced 
AABC subset.
Gene and SNP selection
Table 1 shows the list of the 26 genes included in the present analysis. In addition to the four 
FGFR paralog genes (FGFR1, FGFR2, FGR3, and FGFR4), and eight FGF genes (FGF1, 
FGF2, FGF3, FGF4, FGF6, FGF7, FGF9, FGF10) whose products bind to more than one 
FGFR [25], additional selected genes code for proteins that participate in the initial steps of 
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FGF/FGFR signaling or are downstream effectors of the pathway. Tag SNPs were then 
selected for all 26 genes in order to capture (at r2 ≥0.8) as many SNPs as possible with 
minor allele frequency ≥10%, based on the haplotype structure of the Yoruban population 
(YRI) in 1000 Genomes (http://www.1000genomes.org/).
Genotyping and quality control
Genotyping using the Illumina Human Exome Beadchip v1.1 with custom content was 
performed by the Center for Inherited Disease Research (CIDR) (http://
genome.sph.umich.edu/wiki/Exome_Chip_Design). The variants selected were included as 
part of the more than 159,000 custom content SNPs added to the Exome Beadchip to 
support the scientific goals of the AMBER consortium.
Of the 405,555 SNPs attempted for genotyping, 381,212 were released by CIDR and 
299,873 of these remained after removing SNPs that were monomorphic, were positional 
duplicates, were on the Y chromosome, had Hardy-Weinberg Equilibrium (HWE) 
P<1×10−4, had call rate < 0.98, had > 1 Mendelian errors in trios from HapMap (http://
hapmap.ncbi.nlm.nih.gov), or had > 2 discordant calls in duplicate samples. Of these 
remaining variants, 1691 SNPs were in the genes of interest for the present analyses. 
Genotypes were attempted for 6936 study subjects from the BWHS, CBCS, and WCHS, and 
were completed with call rate > 98% for 6828 participants (3130 cases, 3698 controls). The 
University of Washington (UW) performed imputation using the IMPUTE2 software [26] 
and the 1000 Genomes Phase I reference panel (5/21/2011 1000 Genomes data, December 
2013 haplotype release on the IMPUTE2 website: https://mathgen.stats.ox.ac.uk/impute/
impute_v2.html#reference.
Genetic data from 533 cases and 989 controls in the MEC study had been genotyped on the 
Illumina Human 1M-Duo array and SNPs were imputed from 1000 Genomes. MEC’s 
imputed genotypes were combined with the imputed data for the BWHS, CBCS, and WCHS 
into a final data set after additional quality control. Variants with mismatching alleles or 
allele frequencies that were different by more than 0.15 in MEC vs. the other three studies 
were omitted. Also, SNPs with minor allele frequencies < 0.5% or imputation score INFO < 
0.5 in either study were removed. After these exclusions, there were 9264 genotyped and 
imputed SNPs in the 26 genes of interest.
Genotype principal components were computed using the smartpca program in the 
EIGENSOFT package [27]. Relationship checking using PLINK version 1.07 [28] (http://
pngu.mgh.harvard.edu/~purcell/plink/) identified several relatives among and within the 
individual studies. Related individuals and those with more extreme principal components 
were flagged so that relationships could be taken into account and sensitivity analyses could 
be performed. The principal components of genotype were tested for association with case 
status after accounting for the study covariates: study, age (10 year groupings, matching 
variable), geographic region (matching variable), and DNA source (Oragene-saliva, blood, 
mouthwash-saliva). No principal components were strongly associated with case status after 
controlling for the study covariates. For case status and subtype association analyses, we 
included principal components that were associated in the full covariate model with P < 0.1.
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Statistical Analysis
We conducted gene-based tests for the 26 selected genes in the FGFR signaling pathway. We 
use a multi-locus adaptive joint test [15] as implemented in the R package AdaJoint [29]. 
The test identifies the best subset of SNPs that jointly show the strongest evidence for 
association with disease in a given gene through a variable selection procedure that takes 
into account the LD structure. The significance level of the gene-based test is evaluated 
through a direct simulation approach that generates the null distribution of the statistic. 
Because the score test implemented in AdaJoint is not optimal for rare variants, we excluded 
SNPs with minor allele frequency (MAF) less than 2%. For highly correlated SNPs (r2>0.9), 
we excluded the SNP with the smaller MAF. These exclusions resulted in a final analytic list 
of 3237 SNPs in 26 genes. Our primary analysis searched up to the best pair of SNPs within 
each gene. In secondary analysis we searched up to the best five SNPs within each gene. 
Statistical significance at the gene-based analysis was declared at the 0.002 level (=0.05/26 
genes).
Odds ratios (ORs) and 95% confidence intervals (CIs) for the most significant SNPs on the 
identified genes were estimated using the glm function in R version 3.1.1 (http://www.r-
project.org/). Models were adjusted for the covariates noted above and for genotype 
principal components 5, 6, and 8.
RESULTS
Table 2 shows the distribution of subtypes and age at diagnosis of cases by study site. A total 
of 3663 breast cancer cases (1983 ER+ cases, 1098 ER− cases, and 582 unknown ER status) 
and 4687 controls were included in the present analysis.
Table 3 shows the results of gene-based association analyses based on the top pair of SNPs 
in each gene. Results were similar when we used a gene-based test that examined up to the 
top five SNPs (data not shown). The FGF1 gene was found to be associated with risk of ER− 
breast cancer (P = 0.001). As expected, FGFR2 was associated with risk of overall breast 
cancer (P = 0.002) and ER+ breast cancer (P = 0.002). There was suggestive evidence of an 
association of the MAPK3 gene with ER− breast cancer (P = 0.008).
The most significant risk model for FGF1 was a one-SNP model (rs143172501), which was 
associated with risk of ER− breast cancer at pathway-wide significance (Table 4). The minor 
T-allele (3.6% frequency in AMBER controls) was associated with 88% higher risk of ER− 
breast cancer (P = 1.4×10−6) and 31% higher risk of overall breast cancer (P = 0.005). No 
association was observed for ER+ breast cancer (P = 0.77). In the AABC replication subset, 
there was no association of rs143172501 with ER− breast cancer (P = 0.61). The combined 
odds ratio from the two studies was 1.65 (95% CI 1.30-2.08) (P = 2.7×10−5) for ER− breast 
cancer (Supplementary Table 1).
A 2-SNP model (rs10736303 and rs3135774, r2 = 0.001 between both SNPs) was the most 
significant model for FGFR2 for both overall breast cancer and ER+ breast cancer (Table 4). 
Rs10736303 is a perfect proxy (r2 = 0.99) of rs2981578, which is the previously reported 
FGFR2 risk variant in African Americans [24]. The rs10736303 major G-allele (84.2% 
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frequency) was associated with 25% higher risk of overall breast cancer (P = 3.3×10−6), 
30% higher risk of ER+ breast cancer (P = 8.4×10−6), and 21% higher risk was observed for 
ER− breast cancer (P = 0.01). The rs3135774 minor C-allele (2.2% frequency) was 
associated with 47% higher risk of overall breast cancer (P = 4.9×10−4), and 62% higher risk 
of ER+ breast cancer (2.1×10−4). Rs3135774 was not associated with either overall breast 
cancer (P = 0.81) or ER+ breast cancer (P = 0.69) in the AABC subset. Meta-analysis of 
rs3135774 in AMBER and AABC resulted in OR (95% CI) = 1.37 (1.12-1.67) (P = 
2.0×10−3) for overall breast cancer, and 1.48 (1.17-1.87) (P = 1.1×10−3) for ER+ breast 
cancer (Supplementary Table 1).
The suggestive association of MAPK3 with ER− breast cancer was explained by a one-SNP 
model (rs78564187) (Table 4). The minor A-allele (18.0% frequency) was exclusively 
associated with ER− breast cancer, with a 26% higher risk per allele (P = 3.7×10−4). No 
association was observed for either overall breast cancer or ER+ breast cancer. The odds 
ratio for ER− breast cancer in the AABC subset was in the same direction as in AMBER 
data but not statistically significant (P = 0.46). The combined OR (95% CI) from a meta-
analysis of the two consortia was 1.22 (1.09-1.36) (P = 4.9×10−4) (Supplementary Table 1).
DISCUSSION
In this large gene-based analysis of the FGFR signaling pathway, we found that the FGF1 
gene was associated with risk of ER− breast cancer. FGF1 is a member of the FGF 
superfamily in humans and codes for the fibroblast growth factor 1 (FGF1). FGF1 is able to 
bind to the four FGF receptors, and mediates a wide variety of biologic processes such as 
cell migration, proliferation, differentiation, and survival among other functions (see review 
in [30]). Amplification of the FGF1 gene is observed in ovarian cancer and is a predictor of 
poor survival [31].
The gene association was explained by a single SNP (rs143172501) located 9 kb upstream 
of FGF1. The risk allele (T) of rs143172501 is present only in African-ancestry populations 
from 1000 genomes (4% in the combined African populations), and in some Hispanic 
admixed populations (Colombian in Medellin, 1%; and Puerto Rican in Puerto Rico, 1%), 
which may be due to recent admixture with African-ancestry subjects. In AMBER controls, 
the frequency of the risk T-allele was 3.6%. This finding was not replicated in a smaller 
number of ER− cases and controls from a subset of the AABC consortium. Although we had 
excellent power (>80%) to replicate an OR equal to 1.88 (i.e. the point estimate found in 
AMBER), we had only 45% power if the true OR was 1.45 (i.e. the lower bound of the 95% 
CI in the present study). Heterogeneity of effects due to interaction with unmeasured genetic 
and non-genetic factors may also explain in part the lack of replication. Results from recent 
reports support our finding that genetic variation in FGF1 are associated with risk of ER− 
breast cancer. The Breast Cancer Health Disparities Study found a borderline association (P 
= 0.07) of FGF1 with ER−/PR− breast cancer in gene-based analysis, with three common 
SNPs (rs34001, rs152524, and rs34021) showing significant associations with ER−/PR− 
tumors in Hispanic and non-Hispanic white women [10]. In addition, the Guangzhou Breast 
Cancer Study found a significant association of rs250108, located in a transcription factor 
binding site of the first intron of FGF1, with ER− breast cancer in Chinese women [32]. 
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None of these four FGF1 SNPs was associated with risk of ER− tumor in the present study 
(data not shown). Nevertheless, our results as well as those from the Breast Cancer Health 
Disparities Study and the Guangzhou Breast Cancer Study do suggest the presence of 
genetic variation in FGF1 associated with risk of ER− breast cancer although the identity of 
the particular polymorphisms remains elusive. If there are indeed true risk FGF1 variants 
they may differ by ethnic groups as suggested by the different SNPs found by us, and the 
Breast Cancer Health Disparities Study and the Guangzhou Breast Cancer Study.
FGFR2 rs10736303 is perfectly correlated (r2 = 0.99) with rs2981578, which was previously 
identified as the SNP with the strongest association with overall and ER+ breast cancer in 
FGFR2 in African Americans [24]. A recent fine-mapping of FGFR2 identified three 
independent signals in Europeans and East Asians: the first signal represented by 
rs35054928, the second signal by rs45631563, and the third one by rs2981578 [11]. 
However, rs35054928 (signal 1) and rs2981578 (signal 3) show high correlation in 
Europeans (r2 = 0.79) and they most likely represent a single signal. We found in AMBER 
that rs10736303 (proxy of rs2981578, signal 3) is in moderate correlation with rs35054928 
(signal 1) (r2 = 0.27). After adjustment for rs10736303, rs35054928 was no longer 
associated with either overall or ER+ breast cancer (data not shown), suggesting that signal 1 
and signal 3 could be the same signal in African Americans, and is best tagged by 
rs10736303 (or rs2981578). Rs45631563 (signal 2) is a rare variant in African Americans 
(MAF = 0.9% in AMBER controls) suggesting that this signal may be rare in African-
ancestry groups. It is unclear whether there is a second FGFR2 independent signal in 
African Americans. Although we found suggestive evidence of such signal in AMBER 
tagged by rs3135774 (r2 = 0.001 with rs10736303), this result must be interpreted with 
caution given that the association did not replicate in AABC. Because of the low frequency 
of the rs3135774 risk allele insufficient power cannot be ruled out as an explanation of the 
lack of replication.
MAPK3 codes a protein that is member of the mitogen-activated protein (MAP) kinase 
family, which participates in the MAPK/extracellular regulated-signal kinase (ERK) 
pathways. MAPK/ERK pathways integrate a variety of external and internal signals to 
regulate diverse cellular processes such as proliferation, survival, and differentiation among 
others (see review [33]). Although expression and activation of MAPK3 are de-regulated in 
a variety of human cancers including breast [34-37], no GWAS has reported germline 
variants in MAPK3 associated with any type of cancer. It is possible that as one of the final 
effectors of several signaling pathways, MAPK3 activity may be de-regulated by events/
mutations upstream in diverse signaling pathways including the FGF/FGFR pathway. Our 
results suggest that genetic variation in MAPK3 may be associated with risk of ER− breast 
cancer.
In summary, our findings confirm the role of FGFR2 in breast cancer etiology and ER+ 
tumor in particular, and suggest that variants in FGF1 and MAPK3 may affect risk of ER− 
breast cancer. Although the FGF1 SNP association with risk of ER− breast cancer that we 
found in AMBER was not replicated in AABC, recent studies have also reported 
associations of FGF1 variants with ER− tumors in Hispanic, non-Hispanic white, and 
Chinese women [32,10]. Taken together, ours and previous reports suggest the presence of 
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FGF1 gene variants associated with risk of ER− breast cancer although the identity of these 
variants and whether they are the same across different populations are still uncertain. The 
present findings stress the need of further evaluation of the FGFR pathway in relation to 
breast cancer and ER subtypes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
List of selected genes in the FGFR signaling pathway
Gene Chromosome Protein function
SHC1 1q21 Adaptor protein that binds to the FGFRs
IL17RD 3p14 Transmembrane protein. Antagonist of FGF signaling
FGFR3 4p16 Fibroblast growth receptor 3. Tyrosine kinase
KLB 4p14 Klotho beta protein. Helps in the FGF-FGFR binding
FGF2 4q26 Fibroblast growth factor 2
SPRY1 4q28 Antagonist of FGFs signaling
FGF10 5p13 Fibroblast growth factor 10
SPRY4 5q31 Antagonist of FGFs signaling
FGF1 5q31 Fibroblast growth factor 1
FGFR4 5q35 Fibroblast growth factor receptor 4. Tyrosine kinase
FRS3 6p21 FGFR substrate 3. Links FGFRs to downstream activators
FGFR1 8p11 Fibroblast growth factor receptor 1. Tyrosine kinase
FGFR2 10q26 Fibroblast growth factor receptor 2. Tyrosine kinase
FGF4 11q13 Fibroblast growth factor 4
FGF3 11q13 Fibroblast growth factor 3
CBL 11q23 E3 ubiquitin protein ligase. Negative regulator of signaling pathways
FGF6 12p13 Fibroblast growth factor 6
FRS2 12q15 FGFR substrate 2. Links FGFRs to downstream activators
FGF9 13q11 Fibroblast growth factor 9
KL 13q12 Klotho protein. Helps in the FGF-FGFR binding
SPRY2 13q31 Antagonist of FGFs signaling
FGF7 15q21 Fibroblast growth factor 7
MAPK3 16p11 MAP kinase 3. Downstream effector
GRB2 17q24 Downstream effector. Recruits negative regulators
PLCG1 20q12 Phospholipase C gamma 1. Substrate of activated FGFRs
MAPK1 22q11 MAP kinase 1. Downstream effector
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Table 2
Characteristics of participants by study in the AMBER consortium
BWHS CBCS WCHS MEC AMBER
Controls 2249 615 834 989 4687
Cases 901 1408 821 533 3663
 ER+ cases 498 741 435 309 1983
 ER− cases 233 565 165 135 1098
 Unknown ER 170 102 221 89 582
Age at diagnosis
 <40 47 204 85 0 336
 40-49 262 459 215 9 945
 50-59 302 381 292 112 1087
 60-69 204 267 173 175 819
 ≥70 86 97 56 237 476
ER estrogen receptor; BWHS Black Women’s Health Study, CBCS Carolina Breast Cancer Study, WCHS Women’s Circle of Health Study, MEC 
Multi-Ethnic Cohort, AMBER African American Breast Cancer Epidemiology and Risk
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Table 3
P values for gene-based association testsa
Gene Number ofSNPs
Number of
SNPs pruned
in
P valueb
All cases ER+ ER−
SHC1 31 15 0.10 0.11 0.38
IL17RD 581 183 0.81 0.97 0.11
FGFR3 186 117 0.98 0.93 0.61
KLB 343 142 0.50 0.04 0.71
FGF2 620 206 0.83 0.20 0.89
SPRY1 135 66 0.70 0.67 0.86
FGF10 469 118 0.15 0.12 0.07
SPRY4 185 92 0.87 0.83 0.77
FGF1 861 399 0.64 0.90 0.001
FGFR4 181 80 0.48 0.14 0.46
FRS3 126 52 0.33 0.88 0.08
FGFR1 264 95 0.17 0.64 0.37
FGFR2 821 395 0.002 0.002 0.08
FGF4 195 91 0.21 0.39 0.93
FGF3 229 85 0.98 0.96 0.86
CBL 435 99 0.68 0.89 0.58
FGF6 227 116 0.99 0.93 0.68
FRS2 668 155 0.94 0.62 0.99
FGF9 257 129 0.15 0.11 0.18
KL 525 184 0.74 0.95 0.16
SPRY2 128 60 0.32 0.15 0.89
FGF7 356 77 0.38 0.59 0.22
MAPK3 24 11 0.46 0.84 0.008
GRB2 607 110 0.47 0.05 0.13
PLCG1 118 36 0.57 0.36 0.62
MAPK1 692 124 0.91 0.42 0.62
aAdjusted for study site, age (10 year groupings), geographic region, DNA source (saliva, blood, mouthwash), and genotype principal components 
5, 6, and 8
bAn alpha level of 0.002 (=0.05/26 genes) was used to determine statistical significance
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